News
NAVB
--
0.00%
--
Nano-Drug Market Potential Growth, Share, Demand, Analysis of Key Players and Forecasts to 2020 - 2027 By Ameco Research
pune, India, Fri, 16 Apr 2021 05:05:21 / Comserve Inc. / -- A new research report titled "Nano-Drug Market" successfully exhibits the complete scenario of...
Comserve · 1d ago
Sentinel Node Biopsy Market Size 2021 | Impact of Covid-19 on Industry Share, CAGR Status, Trends Analysis, Top Manufacturers, Growth Factor, Drivers, and Global Forecast to 2027
Apr 16, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Sentinel Node Biopsy Market” report...
The Express Wire · 1d ago
Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company’s preclinical studies o...
Business Wire · 1d ago
Navidea Bio World Intellectual Property Organization PatentScope Listing For Co.'s ' COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS'
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021067479&tab=PCTDESCRIPTION
Benzinga · 04/08 19:47
Sentinel Node Biopsy Market Size 2020 : Growth Factors, Defination, Business Opportunity, Trend, Segmentation and Forecast to 2026 Research Report by means of 360 market updates
Apr 08, 2021 (The Expresswire) -- “ Sentinel Node Biopsy Market “ size is expected to raise remarkably, most important trends, impact of COVID-19 , market...
The Express Wire · 04/08 06:49
Navidea Biopharmaceuticals Stock Shows Every Sign Of Being Fairly Valued
GuruFocus News · 04/06 13:38
BRIEF-Navidea Says Board Approved Adoption Of An Amendment To Company's Amended And Restated Bylaws
reuters.com · 04/05 20:23
10-K: NAVIDEA BIOPHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be...
Edgar Online - (EDG = 10Q, 10K) · 03/26 21:03
Navidea (NAVB) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Navidea (NAVB) yesterday and set a price target of $7.00. The company's shares
SmarterAnalyst · 03/26 11:35
Analysts Offer Insights on Healthcare Companies: Navidea (NAVB) and Monopar Therapeutics Inc (MNPR)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Navidea (NAVB) and Monopar Therapeutics Inc (MNPR) with
SmarterAnalyst · 03/25 14:35
DJ Navidea Biopharmaceuticals, Inc. CEO Jed Latkin on Q4 2020 Results -- Earnings Call Transcript >NAVB
Dow Jones · 03/25 04:50
8-K: NAVIDEA BIOPHARMACEUTICALS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- PURSUANT TO SECTION 13 OR 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/24 21:31
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full yea...
Business Wire · 03/24 21:21
Navidea Biopharmaceutical Q4 EPS $(0.11) Beats $(0.12) Estimate, Sales $219.25K Miss $600.00K Estimate
Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 26.67 percent increase over losses of $(0.15) per share
Benzinga · 03/24 20:26
Navidea Biopharm 4Q Loss/Shr 11c >NAVB
Navidea Biopharm 4Q Loss/Shr 11c >NAVB
Dow Jones · 03/24 20:25
Navidea Biopharm 4Q Rev $219,251 >NAVB
Navidea Biopharm 4Q Rev $219,251 >NAVB
Dow Jones · 03/24 20:25
Navidea Biopharm EPS beats by $0.01, misses on revenue
Navidea Biopharm (NAVB): Q4 GAAP EPS of -$0.11 beats by $0.01.Revenue of $0.22M (+83.3% Y/Y) misses by $0.08M.Navidea ended the fourth quarter of 2020 with $2.7 million in cash and
Seekingalpha · 03/24 20:23
Press Release: Navidea Biopharmaceuticals Reports -2-
Dow Jones · 03/24 20:21
Navidea Biopharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 24, 2021 / Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 24, 2021 at 5:00 PM Eastern Time.
ACCESSWIRE · 03/24 19:45
Webull provides a variety of real-time NAVB stock news. You can receive the latest news about NAVIDEA BIOPHARM through multiple platforms. This information may help you make smarter investment decisions.
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.